Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25917391 | 0.84 | ADORA2A (0.32) | ADORA2AADORA2B | |
| SCHEMBL10141579 | 0.79 | ADORA2A (0.35) | ADORA2AADORA2B | |
| SCHEMBL22014920 | 0.73 | GSR (0.34) | ADORA2AADORA2B | |
| SCHEMBL2737301 | 0.69 | ADORA2A (0.41) | ADORA2AADORA2B | |
| SCHEMBL12935855 | 0.69 | ADORA2A (0.36) | ADORA2AADORA2B | |
| SCHEMBL23401945 | 0.67 | ADORA2A (0.35) | ADORA2AADORA2B | |
| SCHEMBL17045358 | 0.67 | ADORA2A (0.39) | ADORA2AADORA2B | |
| SCHEMBL12126022 | 0.66 | ADORA2A (0.34) | ADORA2AADORA2B | |
| SCHEMBL26207419 | 0.66 | — | — | |
| SCHEMBL15069887 | 0.64 | CNR1 (0.34) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ADORA2A 761/4885ADORA2B 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.